U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Nd Labs, Inc. - 510453 - 12/04/2018
  1. Warning Letters

CLOSEOUT LETTER

Nd Labs, Inc. MARCS-CMS 510453 —

Delivery Method:
United Parcel Service

Recipient:
Recipient Name
Michael A. Beller
Recipient Title
Co-Owner
Nd Labs, Inc.
Nd Labs, Inc.

202 Merrick Rd.
Lynbrook, NY 11563
United States

Issuing Office:
Office of Human and Animal Food Operations East Division I

United States


Dear Mr. Beller:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter CMS# 510453, issued on September 1, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Catherine Beer
Director, Compliance Branch
Office of Human and Animal Food Operations East Division 1

Back to Top